Loading...

"Where no one has gone before"

311 views

Loading...

Loading...

Transcript

The interactive transcript could not be loaded.

Loading...

Loading...

Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Jun 1, 2010

http://www.scenesse.com/

Clinuvel Non-Executive Director Jack Wood discusses commercialization.

Clinuvel is developing a breakthrough photoprotective drug, SCENESSE® (afamelanotide), to be administered every 60 days.

SCENESSE® (afamelanotide) is selective in its pharmacologic action by activating skin's own pigment, melanin . It is due to melanin that a physical barrier between skin and light of all wavelengths -particularly UV- is provided.

Medically this is known as photoprotection.

The Clinuvel team worldwide is testing SCENESSE® (afamelanotide) in 5 indications currently in Phase II and III clinical trials.

Eligible for these trials are patients who suffer from UV and light related skin disorders, ranging from those who suffer from porphyrias to those affected by skin cancer.

(Video released August 2009)

http://www.clinuvel.com

Comments are disabled for this video.
When autoplay is enabled, a suggested video will automatically play next.

Up next


to add this to Watch Later

Add to

Loading playlists...